MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/qad.0000000000004041

Медицинская библиотека · AIDS (London, England) · 2024

Birth outcomes following bictegravir exposure during pregnancy.

Olivero Rosemary, Williams Paige L, Sawyer George, Yee Lynn M, Patel Kunjal, Hernandez-Diaz Sonia, Powis Kathleen, Paul Mary, Chadwick Ellen G, Pediatric HIV/AIDS Cohort Study and the HOPE study

СтатьяПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

OBJECTIVE

Bictegravir is increasingly prescribed as a co-formulated tablet with tenofovir alafenamide and emtricitabine to pregnant persons with HIV (PWH) despite limited pregnancy and birth outcome data. We sought to provide birth outcome data following exposure to bictegravir during pregnancy.

DESIGN

We conducted a descriptive analysis of infants born to pregnant PWH 18-45 years of age enrolled in at least one Pediatric HIV/AIDS Cohort Study (PHACS)-affiliated study who received bictegravir for ≥7 days during pregnancy and completed follow-up through delivery.

METHODS

The outcomes of interest were gestational age at birth, preterm birth (<37 weeks' gestation), gestational-age adjusted birth weight (BWZ) and length (BLZ) Z -scores, small for gestational age (SGA, birthweight <10th percentile), congenital anomalies, neonatal deaths in the first 28 days of life, and infant HIV status.

RESULTS

A total of 177 infants born to 170 unique PWH were exposed to bictegravir for ≥7 days during gestation; 55% were exposed to bictegravir from the time of conception. Median gestational age at birth was 38.1 weeks. The prevalence of preterm birth was 15.8% and SGA was 9.3%. Mean BWZ and BLZ were -0.48 and 0.03. No neonatal deaths or perinatal HIV transmissions were reported. Among 126 infants exposed to first-trimester bictegravir, 7 (5.6%) had major congenital anomalies with no specific pattern suggestive of a syndrome.

CONCLUSIONS

These findings provide preliminary data without significant safety concerns for fetal bictegravir exposure in this United States cohort. Comparative data and continued surveillance of outcomes among infants exposed to bictegravir during gestation are warranted.

Для цитирования: Olivero Rosemary, Williams Paige L, Sawyer George, Yee Lynn M, Patel Kunjal, Hernandez-Diaz Sonia, Powis Kathleen, Paul Mary, Chadwick Ellen G, Pediatric HIV/AIDS Cohort Study and the HOPE study. Birth outcomes following bictegravir exposure during pregnancy.. AIDS (London, England). 2024. DOI: 10.1097/qad.0000000000004041.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.